UB Paderborn / Katalog / Suche / in CDI

Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy

Amyloid, 2023-04, Vol.30 (2), p.208-219

2023

Volltextzugriff (PDF)

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

Drug metabolism and disposition, 2008-08, Vol.36 (8), p.1698

2008

Volltextzugriff (PDF)

PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis

The Journal of pharmacology and experimental therapeutics, 2015-05, Vol.353 (2), p.288

2015

Volltextzugriff (PDF)

Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions

Current drug metabolism, 2007-06, Vol.8 (5), p.407

2007

Volltextzugriff (PDF)

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Journal of clinical pharmacology, 2009-05, Vol.49 (5), p.513-533

2009

Volltextzugriff (PDF)

Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios

Drug metabolism and disposition, 2007-04, Vol.35 (4), p.660

2007

Volltextzugriff (PDF)

A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships

The AAPS journal, 2020-03, Vol.22 (2), p.53, Article 53

2020

Volltextzugriff (PDF)

Editorial: Model-informed decision making in the preclinical stages of pharmaceutical research and development

Frontiers in pharmacology, 2023-04, Vol.14, p.1184914-1184914

2023

Volltextzugriff (PDF)

Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System

Pharmaceutical research, 2016-12, Vol.33 (12), p.3021-3030

2016

Volltextzugriff (PDF)

Physiologically based pharmacokinetic prediction of telmisartan in human

Drug metabolism and disposition, 2014-10, Vol.42 (10), p.1646

2014

Volltextzugriff (PDF)

Clearance in Drug Design

Journal of medicinal chemistry, 2019-03, Vol.62 (5), p.2245

2019

Volltextzugriff (PDF)

Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID‐19 Therapeutics

Clinical pharmacology and therapeutics, 2021-08, Vol.110 (2), p.294-296

Maurer, Tristan S.

2021

Volltextzugriff (PDF)

Relevance of Half-Life in Drug Design

Journal of medicinal chemistry, 2018-05, Vol.61 (10), p.4273-4282

2018

Volltextzugriff (PDF)

Volume of Distribution in Drug Design

Journal of medicinal chemistry, 2015-08, Vol.58 (15), p.5691-5698

2015

Volltextzugriff (PDF)

Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds

The AAPS journal, 2016-05, Vol.18 (3), p.746-756

2016

Volltextzugriff (PDF)

A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling

Journal of pharmacokinetics and pharmacodynamics, 2014-06, Vol.41 (3), p.197-209

2014

Volltextzugriff (PDF)

Dose Predictions for Drug Design

Journal of medicinal chemistry, 2020-06, Vol.63 (12), p.6423-6435

2020

Volltextzugriff (PDF)

Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice

Drug metabolism and disposition, 2005-01, Vol.33 (1), p.175

2005

Volltextzugriff (PDF)

Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies

PloS one, 2016-05, Vol.11 (5), p.e0155674

2016

Volltextzugriff (PDF)

Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery

Biopharmaceutics & drug disposition, 2002-11, Vol.23 (8), p.327-338

2002

Volltextzugriff (PDF)

Quantitative Model‐Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination

Clinical pharmacology and therapeutics, 2024-05, Vol.115 (5), p.1114-1121

2024

Volltextzugriff (PDF)

Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction

Drug metabolism and disposition, 2006-10, Vol.34 (10), p.1742

2006

Volltextzugriff (PDF)

In silico modeling of nonspecific binding to human liver microsomes

Drug metabolism and disposition, 2008-10, Vol.36 (10), p.2130

2008

Volltextzugriff (PDF)

Theoretical Considerations for Direct Translation of Unbound Liver-to-Plasma Partition Coefficient from In Vitro to In Vivo

The AAPS journal, 2019-05, Vol.21 (3), p.43-43, Article 43

2019

Volltextzugriff (PDF)

Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development

Pharmaceutical research, 2022-07, Vol.39 (7), p.1321-1341

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis

Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios

A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships

Editorial: Model-informed decision making in the preclinical stages of pharmaceutical research and development

Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System

Physiologically based pharmacokinetic prediction of telmisartan in human

Clearance in Drug Design

Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID‐19 Therapeutics

Relevance of Half-Life in Drug Design

Volume of Distribution in Drug Design

Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds

A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling

Dose Predictions for Drug Design

Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice

Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies

Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery

Quantitative Model‐Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination

Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction

In silico modeling of nonspecific binding to human liver microsomes

Theoretical Considerations for Direct Translation of Unbound Liver-to-Plasma Partition Coefficient from In Vitro to In Vivo

Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development

Suchergebnisse filtern